Potential of icosabutate as a novel approach to the treatment of NASH highlighted in late-breaker at The International Liver CongressTM 2018

Naarden, The Netherlands, 12 April 2018 – NorthSea Therapeutics B.V., (‘NST’) a newly established Dutch biotech company aiming to develop novel and innovative strategies for the treatment of NASH and other metabolic, inflammatory and fibrotic diseases, announces the publication of a late-breaker abstract and poster to be presented at The EASL International Liver CongressTM 2018 in Paris on 12-14 April.

“We believe icosabutate has the potential to impact the lives of millions of NASH patients globally”
Rob de Ree

Chief Executive Officer, NorthSea Therapeutics

Voor meer informatie:

+31 (0) 35 760 65 05